Literature DB >> 22810175

Development of optimal medium for production of commercially important monoclonal antibody 520C9 by hybridoma cell.

Sucharita Sen1, Pradip K Roychoudhury.   

Abstract

Hybridoma HB-8696 produces monoclonal antibody (mAb) 520C9 (mouse IgG(1)), which recognizes breast cancer oncoprotein c-erbB2. The objective of this study was to optimize the medium recipe of HB 8696 cell for production of mAb 520C9. The optimization consisted of two steps: (1) screening of significant nutrients to make subsequent experiments more efficient with less runs and (2) locating their optimal concentrations. 29 variables including essential and non-essential amino acids, glucose, serum and 6 salts, namely NaCl, KCl, CaCl(2), NaH(2)PO(4), MgSO(4) and Na-pyruvate were chosen in screening phase. The Plackett-Burman method was used to screen the variables influencing mAb production. Seven factors namely glucose, serum, asparagine, threonine, serine, NaCl and NaH(2)PO(4) were identified to have a positive influencing role on mAb production with a confidence level >90 % (p < 0.1). Finally, Response surface methodology revealed the optimal level of the variables. The mAb production and average specific mAb production rate were enhanced by 111.05 and 105 %, respectively, compared to control medium.

Entities:  

Year:  2012        PMID: 22810175      PMCID: PMC3560879          DOI: 10.1007/s10616-012-9480-z

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  41 in total

1.  Statistical methods in media optimization for batch and fed-batch animal cell culture.

Authors:  Diliny M De Alwis; Roshni L Dutton; Jeno Scharer; Murray Moo-Young
Journal:  Bioprocess Biosyst Eng       Date:  2007-01-23       Impact factor: 3.210

2.  Factors controlling cell proliferation and antibody production in mouse hybridoma cells: I. Influence of the amino acid supply.

Authors:  D Duval; C Demangel; K Munier-Jolain; S Miossec; I Geahel
Journal:  Biotechnol Bioeng       Date:  1991-09       Impact factor: 4.530

3.  Effect of serum concentration on hybridoma cell growth and monoclonal antibody production at various initial cell densities.

Authors:  G M Lee; T K Huard; B O Palsson
Journal:  Hybridoma       Date:  1989-06

4.  Microchemical determination of organic nitrogen with Nessler reagent.

Authors:  G R Morrison
Journal:  Anal Biochem       Date:  1971-10       Impact factor: 3.365

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Phosphate feeding improves high-cell-concentration NS0 myeloma culture performance for monoclonal antibody production.

Authors:  V M deZengotita; W M Miller; J G Aunins; W Zhou
Journal:  Biotechnol Bioeng       Date:  2000-09-05       Impact factor: 4.530

7.  Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

Authors:  Michael F Press; Guido Sauter; Leslie Bernstein; Ivonne E Villalobos; Martina Mirlacher; Jian-Yuan Zhou; Rooba Wardeh; Yong-Tian Li; Roberta Guzman; Yanling Ma; Jane Sullivan-Halley; Angela Santiago; Jinha M Park; Alessandro Riva; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

Review 8.  Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer.

Authors:  Jan Trøst Jørgensen; Kirsten Vang Nielsen; Bent Ejlertsen
Journal:  Oncologist       Date:  2007-04

9.  Transient responses of hybridoma cells to nutrient additions in continuous culture: I. Glucose pulse and step changes.

Authors:  W M Miller; C R Wilke; H W Blanch
Journal:  Biotechnol Bioeng       Date:  1989-01-20       Impact factor: 4.530

10.  Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

Authors:  R Repp; H H van Ojik; T Valerius; G Groenewegen; G Wieland; C Oetzel; B Stockmeyer; W Becker; M Eisenhut; H Steininger; Y M Deo; G H Blijham; J R Kalden; J G J van de Winkel; M Gramatzki
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

View more
  4 in total

1.  Facile development of medium optimization for antibody production: implementation in spinner flask and hollow fiber reactor.

Authors:  Chi-Hsien Liu; Yi-Xin Liu; Wei-Chi Wu
Journal:  Cytotechnology       Date:  2018-10-03       Impact factor: 2.058

2.  Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody.

Authors:  Fatemeh Torkashvand; Behrouz Vaziri; Shayan Maleknia; Amir Heydari; Manouchehr Vossoughi; Fatemeh Davami; Fereidoun Mahboudi
Journal:  PLoS One       Date:  2015-10-19       Impact factor: 3.240

Review 3.  Antibody Engineering for Pursuing a Healthier Future.

Authors:  Abdullah F U H Saeed; Rongzhi Wang; Sumei Ling; Shihua Wang
Journal:  Front Microbiol       Date:  2017-03-28       Impact factor: 5.640

4.  A Single Dynamic Metabolic Model Can Describe mAb Producing CHO Cell Batch and Fed-Batch Cultures on Different Culture Media.

Authors:  Julien Robitaille; Jingkui Chen; Mario Jolicoeur
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.